Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.

Frontiers in immunology - 1 Jan 2021

Zou Xue-Lin, Li Xiao-Bo, Ke Hua, Zhang Guang-Yan, Tang Qing, Yuan Jiao, Zhou Chen-Jiao, Zhang Ji-Liang, Zhang Rui, Chen Wei-Yong

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have made great progress in the field of tumors and have become a promising direction of tumor treatment. With advancements in genomics and bioinformatics technology, it is possible to individually analyze the neoantigens produced by somatic mutations of each patient. Neoantigen load (NAL), a promising biomarker for predicting the efficacy of ICIs, has been extensively studied....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Proteins
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Epitopes

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Source

Open in PubMed Open full text

Identifiers

PMID: 34992591
DOI: 10.3389/fimmu.2021.689076
PMCID: PMC8724026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.PMID 34992591Read ↗

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read ↗

Cancer neoantigens as potential targets for immunotherapy.Semantic proximity Read ↗

The Role of Neoantigens in Cancer ImmunotherapySemantic proximity Read ↗

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read ↗

Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.Semantic proximity Read ↗

Advances and challenges in neoantigen prediction for cancer immunotherapySemantic proximity Read ↗

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Semantic proximity Read ↗

Tumor Neoantigenicity Assessment with CSiN Score Incorporates Clonality and Immunogenicity to Predict Immunotherapy OutcomesSemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

New emerging targets in cancer immunotherapy: the role of neoantigensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.